等待开盘 06-26 09:30:00 美东时间
-3.570
-1.55%
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca trial setback.
06-18 00:54
Jazz Pharma (JAZZ) revenue growth driven by Ziihera adoption as 1L treatment for HER2+ GEA, says BofA analyst.
06-11 00:44
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep
06-04 19:50
The Q4 earnings report for Jazz Pharmaceuticals (NASDAQ:JAZZ) was released on T...
02-25 05:08
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $210 to $235.
01-12 17:46
(来源:京城夜读) 收盘总结 创业板指放量大涨1.73%、沪指险守3500点!两市下跌个股超4000只 AI产业链全线爆发。三大指数全天表现分化,收盘涨跌不一...
2025-07-15 19:43
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-03-11 00:16
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $140 price target.
2024-09-09 23:43
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024,
2024-09-09 20:00